- In April 2023, OncoOne GmbH, a biotech firm focused on innovative cancer therapeutics, announced preclinical progress in its WNT pathway inhibitor pipeline targeting solid tumors. The company's lead compound demonstrated promising anti-tumor efficacy in multiple in vivo models by selectively modulating WNT signaling involved in tumor proliferation and immune evasion. This development underscores OncoOne’s strategic focus on advancing first-in-class WNT-targeted therapies to address unmet needs in oncology
- In March 2023, Certa Therapeutics, an Australian biotechnology company, initiated a Phase II clinical trial evaluating its WNT pathway-targeting drug FT011 in patients with systemic sclerosis. The trial aims to assess the drug's efficacy in reversing fibrosis by inhibiting dysregulated WNT signaling pathways associated with disease progression. This milestone reflects growing interest in WNT modulation for fibrotic and autoimmune disorders and highlights Certa’s dedication to translating molecular insights into clinical solutions
- In March 2023, Novartis AG announced a collaboration with the Broad Institute of MIT and Harvard to accelerate research into WNT signaling inhibitors for colorectal and pancreatic cancers. The initiative leverages advanced CRISPR screening platforms and high-throughput compound libraries to identify next-generation WNT modulators. This partnership reflects Novartis’ ongoing investment in targeted oncology and underscores the therapeutic potential of WNT pathway blockade in difficult-to-treat malignancies
- In February 2023, Surrozen Inc., a clinical-stage biotechnology company, reported encouraging Phase I data for SZN-1326, its lead WNT pathway agonist intended for inflammatory bowel disease (IBD). Unsuch as conventional inhibitors, this biologic aims to restore epithelial tissue integrity by modulating WNT activity. The results mark a pivotal step toward a new therapeutic class and reinforce Surrozen’s commitment to precision WNT-targeted therapies in regenerative medicine and gastrointestinal disorders
- In January 2023, Mereo BioPharma Group plc shared updated findings from its ASTEROID Phase II trial assessing the WNT pathway inhibitor setrusumab in patients with osteogenesis imperfecta. The data revealed significant improvements in bone mineral density and fracture reduction, indicating the clinical value of WNT modulation in rare bone diseases. This development emphasizes Mereo’s leadership in rare disease therapeutics and reflects broader momentum in repurposing WNT inhibitors beyond oncology
